Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin

We report on the preparation of a new type of immunotoxin via in vitro ligation of the αHer2 antigen binding fragment (Fab) of the clinically-validated antibody trastuzumab to the plant toxin gelonin, employing catalysis by the bacterial enzyme sortase A (SrtA). The αHer2 Fab was fused with the exte...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:mAbs 2014-03, Vol.6 (2), p.354-366
Hauptverfasser: Kornberger, Petra, Skerra, Arne
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 366
container_issue 2
container_start_page 354
container_title mAbs
container_volume 6
creator Kornberger, Petra
Skerra, Arne
description We report on the preparation of a new type of immunotoxin via in vitro ligation of the αHer2 antigen binding fragment (Fab) of the clinically-validated antibody trastuzumab to the plant toxin gelonin, employing catalysis by the bacterial enzyme sortase A (SrtA). The αHer2 Fab was fused with the extended SrtA recognition motif LPET↓GLEH 6 at the C-terminus of its heavy chain, thereby preventing interference with antigen binding, while the toxin was equipped with a Gly 2 sequence at its N-terminus, distant to the catalytically active site in the C-terminal region. Site-specific in vitro transpeptidation led to a novel antibody-toxin conjugate wherein gelonin had effectively replaced the Fc region of a conventional (monomerized) immunoglobulin. After optimization of reaction conditions and incubation time, the resulting Fab-Gelonin ligation product was purified to homogeneity in a two-step procedure by means of Strep-Tactin affinity chromatography-utilizing the Strep-tag II appended to gelonin-and size exclusion chromatography. Binding activity of the immunotoxin for the Her2 ectodomain was indistinguishable from the unligated Fab as measured by real-time surface plasmon resonance spectroscopy. Specific cytotoxic potency of Fab-Gelonin was demonstrated against two Her2-positive cell lines, resulting in EC 50 values of ~1 nM or lower, indicating a 1000-fold enhanced cell-killing activity compared with gelonin itself. Thus, our strategy provides a convenient route to the modular construction of functional immunotoxins from Fabs of established tumor-specific antibodies with gelonin or related proteotoxins, also avoiding the elevated biosafety levels that would be mandatory for the direct biotechnological preparation of corresponding fusion proteins.
doi_str_mv 10.4161/mabs.27444
format Article
fullrecord <record><control><sourceid>pubmed_infor</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3984325</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>24492291</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-8f4735372338e715518624d0cb4e38d040f8590eff173eea370335c2c2e71e863</originalsourceid><addsrcrecordid>eNptkU1r3DAQhkVpaUKaS39A0bngVF9e2ZdCCPkoBAL5OIuxPNqo2NIiadNsjvnltbvJkkJ0GA3MM-8w8xLylbMjxRf8xwhdPhJaKfWB7PNWiYo1mn3c5QuxRw5z_s3mpxnX7DPZE0q1QrR8nzzfxFQgY2WhwLB5wp76QB98SZG6dbDFxwCDf4I5odFRoBen16LKK7TeeUsT2jh2PkAo9Aw66mKiZT3OEdISiw_Lua3cI10NM2Q3JZb4OE1Z4hCDD1_IJwdDxsOX_4DcnZ3enlxUl1fnv06OLyurWlaqxikta6mFlA1qXtd82k31zHYKZdMzxVxTtwyd41oigtRMytoKKyYam4U8ID-3uqt1N2JvMZQEg1klP0LamAje_F8J_t4s44ORbaOkqCeB71sBm2LOCd2ulzMzm2FmM8w_Myb429tpO_T19BNQbwEfppuN8CemoTcFNkNMLkGwPhv5jvBfpFSaxA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Kornberger, Petra ; Skerra, Arne</creator><creatorcontrib>Kornberger, Petra ; Skerra, Arne</creatorcontrib><description>We report on the preparation of a new type of immunotoxin via in vitro ligation of the αHer2 antigen binding fragment (Fab) of the clinically-validated antibody trastuzumab to the plant toxin gelonin, employing catalysis by the bacterial enzyme sortase A (SrtA). The αHer2 Fab was fused with the extended SrtA recognition motif LPET↓GLEH 6 at the C-terminus of its heavy chain, thereby preventing interference with antigen binding, while the toxin was equipped with a Gly 2 sequence at its N-terminus, distant to the catalytically active site in the C-terminal region. Site-specific in vitro transpeptidation led to a novel antibody-toxin conjugate wherein gelonin had effectively replaced the Fc region of a conventional (monomerized) immunoglobulin. After optimization of reaction conditions and incubation time, the resulting Fab-Gelonin ligation product was purified to homogeneity in a two-step procedure by means of Strep-Tactin affinity chromatography-utilizing the Strep-tag II appended to gelonin-and size exclusion chromatography. Binding activity of the immunotoxin for the Her2 ectodomain was indistinguishable from the unligated Fab as measured by real-time surface plasmon resonance spectroscopy. Specific cytotoxic potency of Fab-Gelonin was demonstrated against two Her2-positive cell lines, resulting in EC 50 values of ~1 nM or lower, indicating a 1000-fold enhanced cell-killing activity compared with gelonin itself. Thus, our strategy provides a convenient route to the modular construction of functional immunotoxins from Fabs of established tumor-specific antibodies with gelonin or related proteotoxins, also avoiding the elevated biosafety levels that would be mandatory for the direct biotechnological preparation of corresponding fusion proteins.</description><identifier>ISSN: 1942-0862</identifier><identifier>ISSN: 1942-0870</identifier><identifier>EISSN: 1942-0870</identifier><identifier>EISSN: 1942-0862</identifier><identifier>DOI: 10.4161/mabs.27444</identifier><identifier>PMID: 24492291</identifier><language>eng</language><publisher>United States: Taylor &amp; Francis</publisher><subject>Adenocarcinoma - immunology ; Adenocarcinoma - therapy ; Aminoacyltransferases - metabolism ; Antibodies, Monoclonal, Humanized - genetics ; Antibodies, Monoclonal, Humanized - metabolism ; Antibody-Dependent Cell Cytotoxicity ; antibody-drug conjugate ; Bacterial Proteins - metabolism ; binding protein ; Breast Neoplasms - immunology ; Breast Neoplasms - therapy ; Catalysis ; Cell Line, Tumor ; Chromatography, Affinity ; Cysteine Endopeptidases - metabolism ; Female ; Humans ; Immunoglobulin Fab Fragments - genetics ; Immunoglobulin Fab Fragments - metabolism ; Immunotherapy, Active - methods ; immunotoxin ; Molecular Targeted Therapy ; Ovarian Neoplasms - immunology ; Ovarian Neoplasms - therapy ; plant toxin ; protein ligation ; Receptor, ErbB-2 - immunology ; Receptor, ErbB-2 - metabolism ; Recombinant Fusion Proteins - genetics ; Recombinant Fusion Proteins - metabolism ; Ribosome Inactivating Proteins, Type 1 - genetics ; Ribosome Inactivating Proteins, Type 1 - metabolism ; transpeptidation ; Trastuzumab</subject><ispartof>mAbs, 2014-03, Vol.6 (2), p.354-366</ispartof><rights>Copyright © 2014 Landes Bioscience 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c490t-8f4735372338e715518624d0cb4e38d040f8590eff173eea370335c2c2e71e863</citedby><cites>FETCH-LOGICAL-c490t-8f4735372338e715518624d0cb4e38d040f8590eff173eea370335c2c2e71e863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984325/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984325/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24492291$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kornberger, Petra</creatorcontrib><creatorcontrib>Skerra, Arne</creatorcontrib><title>Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin</title><title>mAbs</title><addtitle>MAbs</addtitle><description>We report on the preparation of a new type of immunotoxin via in vitro ligation of the αHer2 antigen binding fragment (Fab) of the clinically-validated antibody trastuzumab to the plant toxin gelonin, employing catalysis by the bacterial enzyme sortase A (SrtA). The αHer2 Fab was fused with the extended SrtA recognition motif LPET↓GLEH 6 at the C-terminus of its heavy chain, thereby preventing interference with antigen binding, while the toxin was equipped with a Gly 2 sequence at its N-terminus, distant to the catalytically active site in the C-terminal region. Site-specific in vitro transpeptidation led to a novel antibody-toxin conjugate wherein gelonin had effectively replaced the Fc region of a conventional (monomerized) immunoglobulin. After optimization of reaction conditions and incubation time, the resulting Fab-Gelonin ligation product was purified to homogeneity in a two-step procedure by means of Strep-Tactin affinity chromatography-utilizing the Strep-tag II appended to gelonin-and size exclusion chromatography. Binding activity of the immunotoxin for the Her2 ectodomain was indistinguishable from the unligated Fab as measured by real-time surface plasmon resonance spectroscopy. Specific cytotoxic potency of Fab-Gelonin was demonstrated against two Her2-positive cell lines, resulting in EC 50 values of ~1 nM or lower, indicating a 1000-fold enhanced cell-killing activity compared with gelonin itself. Thus, our strategy provides a convenient route to the modular construction of functional immunotoxins from Fabs of established tumor-specific antibodies with gelonin or related proteotoxins, also avoiding the elevated biosafety levels that would be mandatory for the direct biotechnological preparation of corresponding fusion proteins.</description><subject>Adenocarcinoma - immunology</subject><subject>Adenocarcinoma - therapy</subject><subject>Aminoacyltransferases - metabolism</subject><subject>Antibodies, Monoclonal, Humanized - genetics</subject><subject>Antibodies, Monoclonal, Humanized - metabolism</subject><subject>Antibody-Dependent Cell Cytotoxicity</subject><subject>antibody-drug conjugate</subject><subject>Bacterial Proteins - metabolism</subject><subject>binding protein</subject><subject>Breast Neoplasms - immunology</subject><subject>Breast Neoplasms - therapy</subject><subject>Catalysis</subject><subject>Cell Line, Tumor</subject><subject>Chromatography, Affinity</subject><subject>Cysteine Endopeptidases - metabolism</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulin Fab Fragments - genetics</subject><subject>Immunoglobulin Fab Fragments - metabolism</subject><subject>Immunotherapy, Active - methods</subject><subject>immunotoxin</subject><subject>Molecular Targeted Therapy</subject><subject>Ovarian Neoplasms - immunology</subject><subject>Ovarian Neoplasms - therapy</subject><subject>plant toxin</subject><subject>protein ligation</subject><subject>Receptor, ErbB-2 - immunology</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Recombinant Fusion Proteins - genetics</subject><subject>Recombinant Fusion Proteins - metabolism</subject><subject>Ribosome Inactivating Proteins, Type 1 - genetics</subject><subject>Ribosome Inactivating Proteins, Type 1 - metabolism</subject><subject>transpeptidation</subject><subject>Trastuzumab</subject><issn>1942-0862</issn><issn>1942-0870</issn><issn>1942-0870</issn><issn>1942-0862</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkU1r3DAQhkVpaUKaS39A0bngVF9e2ZdCCPkoBAL5OIuxPNqo2NIiadNsjvnltbvJkkJ0GA3MM-8w8xLylbMjxRf8xwhdPhJaKfWB7PNWiYo1mn3c5QuxRw5z_s3mpxnX7DPZE0q1QrR8nzzfxFQgY2WhwLB5wp76QB98SZG6dbDFxwCDf4I5odFRoBen16LKK7TeeUsT2jh2PkAo9Aw66mKiZT3OEdISiw_Lua3cI10NM2Q3JZb4OE1Z4hCDD1_IJwdDxsOX_4DcnZ3enlxUl1fnv06OLyurWlaqxikta6mFlA1qXtd82k31zHYKZdMzxVxTtwyd41oigtRMytoKKyYam4U8ID-3uqt1N2JvMZQEg1klP0LamAje_F8J_t4s44ORbaOkqCeB71sBm2LOCd2ulzMzm2FmM8w_Myb429tpO_T19BNQbwEfppuN8CemoTcFNkNMLkGwPhv5jvBfpFSaxA</recordid><startdate>20140301</startdate><enddate>20140301</enddate><creator>Kornberger, Petra</creator><creator>Skerra, Arne</creator><general>Taylor &amp; Francis</general><general>Landes Bioscience</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20140301</creationdate><title>Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin</title><author>Kornberger, Petra ; Skerra, Arne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-8f4735372338e715518624d0cb4e38d040f8590eff173eea370335c2c2e71e863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adenocarcinoma - immunology</topic><topic>Adenocarcinoma - therapy</topic><topic>Aminoacyltransferases - metabolism</topic><topic>Antibodies, Monoclonal, Humanized - genetics</topic><topic>Antibodies, Monoclonal, Humanized - metabolism</topic><topic>Antibody-Dependent Cell Cytotoxicity</topic><topic>antibody-drug conjugate</topic><topic>Bacterial Proteins - metabolism</topic><topic>binding protein</topic><topic>Breast Neoplasms - immunology</topic><topic>Breast Neoplasms - therapy</topic><topic>Catalysis</topic><topic>Cell Line, Tumor</topic><topic>Chromatography, Affinity</topic><topic>Cysteine Endopeptidases - metabolism</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulin Fab Fragments - genetics</topic><topic>Immunoglobulin Fab Fragments - metabolism</topic><topic>Immunotherapy, Active - methods</topic><topic>immunotoxin</topic><topic>Molecular Targeted Therapy</topic><topic>Ovarian Neoplasms - immunology</topic><topic>Ovarian Neoplasms - therapy</topic><topic>plant toxin</topic><topic>protein ligation</topic><topic>Receptor, ErbB-2 - immunology</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Recombinant Fusion Proteins - genetics</topic><topic>Recombinant Fusion Proteins - metabolism</topic><topic>Ribosome Inactivating Proteins, Type 1 - genetics</topic><topic>Ribosome Inactivating Proteins, Type 1 - metabolism</topic><topic>transpeptidation</topic><topic>Trastuzumab</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kornberger, Petra</creatorcontrib><creatorcontrib>Skerra, Arne</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>mAbs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kornberger, Petra</au><au>Skerra, Arne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin</atitle><jtitle>mAbs</jtitle><addtitle>MAbs</addtitle><date>2014-03-01</date><risdate>2014</risdate><volume>6</volume><issue>2</issue><spage>354</spage><epage>366</epage><pages>354-366</pages><issn>1942-0862</issn><issn>1942-0870</issn><eissn>1942-0870</eissn><eissn>1942-0862</eissn><abstract>We report on the preparation of a new type of immunotoxin via in vitro ligation of the αHer2 antigen binding fragment (Fab) of the clinically-validated antibody trastuzumab to the plant toxin gelonin, employing catalysis by the bacterial enzyme sortase A (SrtA). The αHer2 Fab was fused with the extended SrtA recognition motif LPET↓GLEH 6 at the C-terminus of its heavy chain, thereby preventing interference with antigen binding, while the toxin was equipped with a Gly 2 sequence at its N-terminus, distant to the catalytically active site in the C-terminal region. Site-specific in vitro transpeptidation led to a novel antibody-toxin conjugate wherein gelonin had effectively replaced the Fc region of a conventional (monomerized) immunoglobulin. After optimization of reaction conditions and incubation time, the resulting Fab-Gelonin ligation product was purified to homogeneity in a two-step procedure by means of Strep-Tactin affinity chromatography-utilizing the Strep-tag II appended to gelonin-and size exclusion chromatography. Binding activity of the immunotoxin for the Her2 ectodomain was indistinguishable from the unligated Fab as measured by real-time surface plasmon resonance spectroscopy. Specific cytotoxic potency of Fab-Gelonin was demonstrated against two Her2-positive cell lines, resulting in EC 50 values of ~1 nM or lower, indicating a 1000-fold enhanced cell-killing activity compared with gelonin itself. Thus, our strategy provides a convenient route to the modular construction of functional immunotoxins from Fabs of established tumor-specific antibodies with gelonin or related proteotoxins, also avoiding the elevated biosafety levels that would be mandatory for the direct biotechnological preparation of corresponding fusion proteins.</abstract><cop>United States</cop><pub>Taylor &amp; Francis</pub><pmid>24492291</pmid><doi>10.4161/mabs.27444</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1942-0862
ispartof mAbs, 2014-03, Vol.6 (2), p.354-366
issn 1942-0862
1942-0870
1942-0870
1942-0862
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3984325
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Adenocarcinoma - immunology
Adenocarcinoma - therapy
Aminoacyltransferases - metabolism
Antibodies, Monoclonal, Humanized - genetics
Antibodies, Monoclonal, Humanized - metabolism
Antibody-Dependent Cell Cytotoxicity
antibody-drug conjugate
Bacterial Proteins - metabolism
binding protein
Breast Neoplasms - immunology
Breast Neoplasms - therapy
Catalysis
Cell Line, Tumor
Chromatography, Affinity
Cysteine Endopeptidases - metabolism
Female
Humans
Immunoglobulin Fab Fragments - genetics
Immunoglobulin Fab Fragments - metabolism
Immunotherapy, Active - methods
immunotoxin
Molecular Targeted Therapy
Ovarian Neoplasms - immunology
Ovarian Neoplasms - therapy
plant toxin
protein ligation
Receptor, ErbB-2 - immunology
Receptor, ErbB-2 - metabolism
Recombinant Fusion Proteins - genetics
Recombinant Fusion Proteins - metabolism
Ribosome Inactivating Proteins, Type 1 - genetics
Ribosome Inactivating Proteins, Type 1 - metabolism
transpeptidation
Trastuzumab
title Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T07%3A02%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sortase-catalyzed%20in%20vitro%20functionalization%20of%20a%20HER2-specific%20recombinant%20Fab%20for%20tumor%20targeting%20of%20the%20plant%20cytotoxin%20gelonin&rft.jtitle=mAbs&rft.au=Kornberger,%20Petra&rft.date=2014-03-01&rft.volume=6&rft.issue=2&rft.spage=354&rft.epage=366&rft.pages=354-366&rft.issn=1942-0862&rft.eissn=1942-0870&rft_id=info:doi/10.4161/mabs.27444&rft_dat=%3Cpubmed_infor%3E24492291%3C/pubmed_infor%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/24492291&rfr_iscdi=true